4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 78 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,361 | -29.5% | 264 | 0.0% | 0.00% | – |
| Q2 2023 | $4,770 | +90.0% | 264 | +133.6% | 0.00% | – |
| Q4 2022 | $2,510 | -16.3% | 113 | -69.6% | 0.00% | – |
| Q3 2022 | $3,000 | -40.0% | 372 | -48.6% | 0.00% | – |
| Q2 2022 | $5,000 | -76.2% | 724 | -48.4% | 0.00% | – |
| Q1 2022 | $21,000 | +31.2% | 1,404 | +98.0% | 0.00% | – |
| Q4 2021 | $16,000 | +77.8% | 709 | +123.0% | 0.00% | – |
| Q3 2021 | $9,000 | – | 318 | +1490.0% | 0.00% | – |
| Q2 2021 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |